What is multiple myeloma cancer?

Multiple myeloma is a type of blood cancer that originates in plasma cells, a a form of white blood cell responsible for producing antibodies. In multiple myeloma, malignant plasma cells accumulate in the bone marrow, leading to bone damage, anemia, kidney dysfunction, and a compromised immune system. The term "multiple" refers to the disease often affecting various bones in the body.

Statistics in Canada

According to the Canadian Cancer Society, multiple myeloma accounts for approximately 1.3% of all new cancer cases in males and 1.2% in females. The five-year net survival rate for multiple myeloma in Canada is about 50%, meaning half of the individuals diagnosed with this cancer are expected to survive at least five years post-diagnosis. Each year, around 3,800 Canadians are diagnosed with multiple myeloma, with incidence rates higher among older adults, particularly those over 65.

Advancements in Research

Research into multiple myeloma has advanced significantly, leading to new treatments and improved patient outcomes. Scientists and medical professionals are exploring novel therapies, including immunotherapy, targeted treatments, and stem cell transplants. Clinical trials across Canada are testing innovative drug combinations and personalized medicine approaches to enhance survival rates and quality of life for patients.

Multiple Myeloma Research at London Health Sciences Centre

London Health Sciences Centre (LHSC) is at the forefront of multiple myeloma research and treatment. The hospital’s research teams, in collaboration with Western University and London Health Sciences Centre Research Institute, are actively investigating new therapeutic strategies, including:

• Stem Cell Transplants: LHSC is a leader in autologous stem cell transplantation, a procedure used to help patients rebuild healthy bone marrow after high-dose chemotherapy.
• Immunotherapy and Targeted Therapy: Researchers are exploring advanced treatments, such as CAR T-cell therapy, monoclonal antibodies, and proteasome inhibitors, which specifically target myeloma cells while minimizing damage to healthy tissue.
• Clinical Trials: LHSC offers access to leading-edge clinical trials, providing patients with opportunities to receive experimental treatments before they become widely available.
• Personalized Medicine: By analyzing the genetic makeup of multiple myeloma cases, researchers at LHSC are working toward customized treatment plans tailored to individual patients, improving outcomes and reducing side effects.

How Your Support Helps

Your donations drive research and innovation, helping to:

• Advance Treatments – Fund groundbreaking studies at LHSC and Lawson Health Research Institute.
• Expand Clinical Trials – Provide access to cutting-edge therapies.
• Enhance Patient Care – Improve hospital resources and support programs.
• Develop Personalized Medicine – Tailor treatments for better outcomes.

Every donation, every participant in our event, brings us closer to a cure.